MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim® Therapy for Bowel Control. InterStim Therapy, previously ...
InterStim Therapy is a sacral neuromodulation therapy from Medtronic. InterStim has been regularly used for urinary incontinence for more than a decade, but recently received additional approval as ...
InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, ...
Medtronic MDT recently announced a patent litigation win related to its sacral neuromodulation device and termed it as ‘an important victory’. Specifically, the company’s sacral neuromodulation device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results